221 related articles for article (PubMed ID: 18704226)
21. Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.
Chilin A; Battistutta R; Bortolato A; Cozza G; Zanatta S; Poletto G; Mazzorana M; Zagotto G; Uriarte E; Guiotto A; Pinna LA; Meggio F; Moro S
J Med Chem; 2008 Feb; 51(4):752-9. PubMed ID: 18251491
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
[TBL] [Abstract][Full Text] [Related]
23. Addiction to protein kinase CK2: a common denominator of diverse cancer cells?
Ruzzene M; Pinna LA
Biochim Biophys Acta; 2010 Mar; 1804(3):499-504. PubMed ID: 19665589
[TBL] [Abstract][Full Text] [Related]
24. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.
Vilk G; Weber JE; Turowec JP; Duncan JS; Wu C; Derksen DR; Zien P; Sarno S; Donella-Deana A; Lajoie G; Pinna LA; Li SS; Litchfield DW
Cell Signal; 2008 Nov; 20(11):1942-51. PubMed ID: 18662771
[TBL] [Abstract][Full Text] [Related]
25. Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
Sekiguchi Y; Nakaniwa T; Kinoshita T; Nakanishi I; Kitaura K; Hirasawa A; Tsujimoto G; Tada T
Bioorg Med Chem Lett; 2009 Jun; 19(11):2920-3. PubMed ID: 19414254
[TBL] [Abstract][Full Text] [Related]
26. Validation of protein kinase CK2 as oncological target.
Seeber S; Issinger OG; Holm T; Kristensen LP; Guerra B
Apoptosis; 2005 Aug; 10(4):875-85. PubMed ID: 16133877
[TBL] [Abstract][Full Text] [Related]
27. Features and potentials of ATP-site directed CK2 inhibitors.
Sarno S; Salvi M; Battistutta R; Zanotti G; Pinna LA
Biochim Biophys Acta; 2005 Dec; 1754(1-2):263-70. PubMed ID: 16198160
[TBL] [Abstract][Full Text] [Related]
28. The raison d'être of constitutively active protein kinases: the lesson of CK2.
Pinna LA
Acc Chem Res; 2003 Jun; 36(6):378-84. PubMed ID: 12809523
[TBL] [Abstract][Full Text] [Related]
29. The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules.
Battistutta R; Mazzorana M; Cendron L; Bortolato A; Sarno S; Kazimierczuk Z; Zanotti G; Moro S; Pinna LA
Chembiochem; 2007 Oct; 8(15):1804-9. PubMed ID: 17768728
[TBL] [Abstract][Full Text] [Related]
30. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.
Cozza G; Gianoncelli A; Bonvini P; Zorzi E; Pasquale R; Rosolen A; Pinna LA; Meggio F; Zagotto G; Moro S
ChemMedChem; 2011 Dec; 6(12):2273-86. PubMed ID: 21972104
[TBL] [Abstract][Full Text] [Related]
31. Different properties of four molecular forms of protein kinase CK2 from Saccharomyces cerevisiae.
Domańska K; Zieliński R; Kubiński K; Sajnaga E; Masłyk M; Bretner M; Szyszka R
Acta Biochim Pol; 2005; 52(4):947-51. PubMed ID: 16265593
[TBL] [Abstract][Full Text] [Related]
32. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
Bortolato A; Cozza G; Moro S
Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
[TBL] [Abstract][Full Text] [Related]
34. Study on the anticancer activity of coumarin derivatives by molecular modeling.
Huang XY; Shan ZJ; Zhai HL; Su L; Zhang XY
Chem Biol Drug Des; 2011 Oct; 78(4):651-8. PubMed ID: 21791009
[TBL] [Abstract][Full Text] [Related]
35. Order or chaos? An evaluation of the regulation of protein kinase CK2.
Olsten ME; Litchfield DW
Biochem Cell Biol; 2004 Dec; 82(6):681-93. PubMed ID: 15674436
[TBL] [Abstract][Full Text] [Related]
36. Salicylaldehyde derivatives as new protein kinase CK2 inhibitors.
Prudent R; López-Ramos M; Moucadel V; Barette C; Grierson D; Mouawad L; Florent JC; Lafanechère L; Schmidt F; Cochet C
Biochim Biophys Acta; 2008 Dec; 1780(12):1412-20. PubMed ID: 18674590
[TBL] [Abstract][Full Text] [Related]
37. Resorufin: a lead for a new protein kinase CK2 inhibitor.
Sandholt IS; Olsen BB; Guerra B; Issinger OG
Anticancer Drugs; 2009 Apr; 20(4):238-48. PubMed ID: 19177021
[TBL] [Abstract][Full Text] [Related]
38. Protein kinase CK2 inhibitors: a patent review.
Cozza G; Pinna LA; Moro S
Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
[TBL] [Abstract][Full Text] [Related]
39. The catalytic subunit of human protein kinase CK2 structurally deviates from its maize homologue in complex with the nucleotide competitive inhibitor emodin.
Raaf J; Klopffleisch K; Issinger OG; Niefind K
J Mol Biol; 2008 Mar; 377(1):1-8. PubMed ID: 18242640
[TBL] [Abstract][Full Text] [Related]
40. Development and exploitation of CK2 inhibitors.
Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
